Evommune, Inc. GAAP EPS of -$0.64
Source: SeekingAlpha
2026-05-08 06:40:29 ET
More on Evommune, Inc.
- Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
- Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge
- Evommune raises $125M privately
- Evommune surges on mid-stage trial win for eczema therapy
- Historical earnings data for Evommune, Inc.
Read the full article on Seeking Alpha
For further details see:
Evommune, Inc. GAAP EPS of -$0.64
Evommune Inc.
NASDAQ: EVMN
EVMN Trading
-4.78% G/L:
$11.56 Last:
558,247 Volume:
$11.93 Open:
EVMN Latest News
$915,144,420
15,720,750
0.25%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
